As such, checkpoint inhibitor therapies, inhibiting CTLA4 and PD-L1/PD-1, were revolutionary cancer immunotherapies (CITs) as they restored the ability of CD8+ T cells to recognize and kill cancer cells.36 This evidence concerns the gene CD8A and cancer.